Pudendal Nerve Block With Bupivacaine Alone and Bupivacaine With Methylene Blue for Postoperative Analgesia

Trial Title: Pudendal Nerve Block With Bupivacaine Alone and Bupivacaine With Methylene Blue for Postoperative Analgesia

NCT ID: NCT05990569

Condition: Hemorrhoids
Anal Fissure and Fistula
Perianal Abscess
Perianal Fistula
Pilonidal Sinus
Perianal Skin Tags

Conditions: Official terms:
Pilonidal Sinus
Hemorrhoids
Fissure in Ano
Fistula

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Supportive Care

Masking: None (Open Label)

Intervention:

Intervention type: Other
Intervention name: Ultrasound guided Pudendal nerve block
Description: Ultrasound guided bilateral pudendal nerve block
Arm group label: Arm A
Arm group label: Arm B

Summary: Study Description: The goal of this clinical trial is to compare the duration of postoperative pain relief achieved with two different approaches to pudendal nerve block in patients undergoing elective perianal surgery. The main question this study aims to answer is whether adding Methylene Blue to Bupivacaine pudendal nerve block can prolong postoperative analgesia compared to using Bupivacaine alone. Participants in this study will be individuals with ASA I and II physical status undergoing elective perianal surgery under spinal anesthesia. They will be randomly assigned to one of two groups: 1. Group A (Case Group): Participants will receive a pudendal nerve block with Bupivacaine combined with Methylene Blue. 2. Group B (Control Group): Participants will receive a pudendal nerve block with Bupivacaine alone. The pudendal nerve block will be performed using ultrasound guidance at the level of the ischial spine. The needle tip will be positioned between the Sacro tuberous and sacrospinous ligaments to inject the local anesthetic or the local anesthetic combined with Methylene Blue. Throughout the study, the researchers will monitor the time to the first rescue analgesic, assess pain levels using the Numeric Rating Scale at various time intervals (2, 6, 24, 48 hours, and 7 days), and observe for any side effects or complications related to the intervention. Participants will be closely observed after surgery to assess their pain levels and analgesic requirements. The researchers will also evaluate patient satisfaction using the Likert scale. By comparing the outcomes between the two groups, the study aims to determine if the addition of Methylene Blue to Bupivacaine pudendal nerve block provides superior postoperative analgesia in perianal surgery patients. This information will contribute to the understanding of effective pain management strategies for individuals undergoing perianal surgical procedures and potentially reduce the need for opioids and improve patient outcomes.

Detailed description: Study Description: The aim of this randomized comparative study is to investigate the effectiveness of two different approaches to postoperative analgesia in patients undergoing perianal surgery. The study will compare the use of Bupivacaine alone with Bupivacaine combined with Methylene Blue in a pudendal nerve block. Perianal surgical procedures, such as abscess drainage, fistulectomy, and hemorrhoidectomy, can cause significant postoperative pain. The goal of this study is to find a more effective and prolonged method of pain relief to improve patient comfort and reduce the need for opioids. Participants in this study will be individuals scheduled for elective perianal surgery and classified as ASA I and II. They will be randomly assigned to one of two groups: 1. Group A: Participants will receive a pudendal nerve block with Bupivacaine and Methylene Blue. 2. Group B: Participants will receive a pudendal nerve block with Bupivacaine alone. The pudendal nerve block will be performed under ultrasound guidance at the ischial spine level. The needle will be accurately placed between the Sacro tuberous and sacrospinous ligaments for precise injection of the local anesthetic or the local anesthetic combined with Methylene Blue. Throughout the study, the researchers will closely monitor the participants to assess the time to the first rescue analgesic and pain levels using the Numeric Rating Scale at specific time intervals (2, 6, 24, 48 hours, and 7 days). Additionally, any side effects, allergies, itching, hematoma, infection, or complications like loss of anal sphincter function will be recorded. Patient satisfaction will also be evaluated using the Likert scale to determine the perceived effectiveness of the different approaches to postoperative analgesia. By comparing the outcomes between the two groups, this study aims to determine whether the addition of Methylene Blue to Bupivacaine in a pudendal nerve block can prolong postoperative analgesia in patients undergoing perianal surgery. The findings from this study may contribute valuable insights into improving pain management strategies and enhancing the overall recovery experience for patients undergoing perianal surgical procedures.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - All patients of ASA I and II undergoing elective perianal surgery under spinal anesthesia Exclusion Criteria: 1. Patient's refusal 2. Patient with a history of allergy to the local anesthetic or Methylene blue 3. Bleeding diathesis or coagulopathy 4. Extensive infection at the site of injection 5. Pregnancy and lactating mother 6. Spinal abnormality 7. Patients with neurological deficit

Gender: All

Minimum age: 15 Years

Maximum age: 90 Years

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: Nepal Mediciti Hospital

Address:
City: Lalitpur
Zip: 44700
Country: Nepal

Status: Recruiting

Contact:
Last name: Apurb Sharma, MD

Phone: +9779841221467
Email: apurbsharma1976@gmail.com

Investigator:
Last name: Saurav Raj Khatiwada, MD
Email: Principal Investigator

Investigator:
Last name: Apurb Sharma, MD
Email: Sub-Investigator

Investigator:
Last name: Prajjwal Raj Bhattarai, MD
Email: Sub-Investigator

Start date: August 12, 2023

Completion date: July 2024

Lead sponsor:
Agency: Nepal Mediciti Hospital
Agency class: Other

Source: Nepal Mediciti Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05990569